Zanidatamab Proves Efficacious in Pretreated Biliary Tract Cancer With Potential to Move to the Frontline
The accelerated FDA approval of zanidatamab-hrii (Ziihera) for patients with previously treated HER2-positive biliary tract cancer and an immunohistochemistry (IHC) score of 3+ has filled a need in a space where therapies are limited, and evaluations of …